Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 16, 2008. The document serves as a report of a major shareholder interest notification received from Legal & General Group plc, rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share ownership thresholds and contains no financial statement data.
Material Changes
The material change disclosed is the acquisition of voting rights by Legal & General Group plc and its subsidiaries. On September 12, 2008, the group crossed the 5% voting rights threshold in GlaxoSmithKline plc Ordinary shares.
- Previous Position: Below 5% voting rights.
- Resulting Position: 5.00% of voting rights.
- Total Voting Rights Held: 261,627,964 shares.
- Breakdown: 243,825,427 direct shares (4.66%) and 17,802,537 indirect shares (0.34%).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, specific risks, contingencies, or unusual items. The document is limited to the statutory notification of the shareholding change under DTR 5.8.12.
Investor Verification Checklist
- Verify the total number of voting rights held by Legal & General Group plc (261,627,964) against the total issued share capital (5,226,596,384).
- Confirm the date the 5% threshold was crossed (September 12, 2008) versus the notification date (September 15, 2008).
- Review the chain of controlled undertakings to understand the split between direct holdings (Legal & General Group Plc) and indirect holdings (Legal & General Investment Management Limited).
- Note that this filing contains no operational or financial performance data for the quarter.